WG

Will Gibbs

Healthtech Partner at Octopus Ventures

Greater London, England

Overview

Work Experience

  • Partner

    2013 - Current

    Leading the Health team at Octopus Ventures - one of the most active multi-stage investors in Europe with over 150 portfolio companies and investing $1-200m per year in new investments.

  • Investor Representative

    2024

    The UK's leading D2C multi-condition digital clinic

  • Investor Representative/NED

    2020

    A leading digital health business addressing harmful addictions Octopus led the Series A round in 2020. The Series B was led by Kinnevik in 2021. The Series C was led by Atomico (Growth) in 2023. The company has raised $130m+ in funding to date.

  • Investor Representative/NED

    2019

    Skin and Me is a leading D2C subscription health company tackling acne and other medical skin care challenges. Octopus led the Seed round in 2019. The Company has raised £18.3m in funding to date.

  • Investor Representative/NED

    2022

    Inflow is one of the first fully-integrated remote clinics for ADHD Octopus led the Series A in 2022. The Company has raised $14m in funding to date

  • Investor Representative/NED

    2015 - 2024

    Permutive is a real-time data management platform, hosted on the edge - powering many of the leading global digital publishers data science companies Octopus led the Seed round in 2015. Subsequent rounds have been led by EQT and Softbank. The Company has raised $105m in funding to date.

  • Investor representative/NED

    2021 - 2023

    LVNDR is building an overdue remote digital clinic dedicated to LGBTQ health needs Octopus led the pre-seed round in 2021

  • Investor Representative/NED

    2020 - 2023

    AI powered cancer diagnostics in digital pathology Octopus co-led the Series B in 2021 and the subsequent Series C was led by 83North. The company has raised $120m in funding to date.

  • Investor representative/NED

    2018 - 2023

    Delivering delicious, handmade plant-based food to homes across the UK. Octopus led the Series A round in 2018

  • Board Observer/Investor Representative

    2020 - 2022

    Flexible cell and gene therapy manufacturing platform for cancer treatment

Relevant Websites